{"entity":{"id":"nct05751798","kind":"trial","name":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas","aka":[],"tldr":"A phase 1/2 trial of OSE2101 in non-small-cell lung cancer and small-cell lung cancer, run by OSE Immunotherapeutics, now recruiting.","summary":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas is a phase 1/2 interventional study registered as NCT05751798 by OSE Immunotherapeutics, with 41 participants planned, started 2022-12-20 and due to reach its primary completion in 2029-12. Interventions recorded: Part A: OSE-279 100mg, Part A: OSE-279 300mg, Part A: OSE-279 600mg, Part B: OSE-279 600 mg and OSE2101, Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive. Conditions listed: Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05751798","url":"https://clinicaltrials.gov/study/NCT05751798"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["ose2101"],"companies":["ose-immunotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05751798","phase":"1/2","setting":"A Multicenter, Phase 1/2, Dose-finding and Dose Expansion Study of OSE-279, a PD-1 Blocking Monoclonal Antibody, in Subjects With Advanced Solid Tumors or Lymphomas","sponsor":"OSE Immunotherapeutics","enrolled":41,"outcomes":[]},"route":"/trials/nct05751798/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"ose2101","kind":"drug","name":"OSE2101","route":"/drugs/ose2101/"}],"company":[{"id":"ose-immunotherapeutics","kind":"company","name":"OSE Immunotherapeutics","route":"/companies/ose-immunotherapeutics/"}]}}